Sitamaquine

• CAT Number: I036319
• CAS Number: 57695-04-2
• Molecular Formula: C21H33N3O
• Molecular Weight: 343.515
• Purity: 98%
• Synonyms: Sitamaquine; WR-6026; WR6026; WR 6026
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 1,6-Hexanediamine, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolinyl)-
• InChI: InChI=1S/C21H33N3O/c1-5-24(6-2)14-10-8-7-9-12-22-20-16-18(25-4)15-19-17(3)11-13-23-21(19)20/h11,13,15-16,22H,5-10,12,14H2,1-4H3
• InChIKey: RVAKDGYPIVSYEU-UHFFFAOYSA-N
• SMILES: CC1=CC=NC2=C(NCCCCCCN(CC)CC)C=C(OC)C=C12

Sitamaquine (Cat.No:I036319), also known as WR-6026, is an orally active 8-aminoquinoline analog with anti-leishmanial properties.

Reference

1: Frampton JE. Tafenoquine: First Global Approval. Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2. Review. PubMed PMID: 30229442.
2: Imbert L, Cojean S, Libong D, Chaminade P, Loiseau PM. Sitamaquine-resistance in Leishmania donovani affects drug accumulation and lipid metabolism. Biomed Pharmacother. 2014 Sep;68(7):893-7. doi: 10.1016/j.biopha.2014.08.009. Epub 2014 Aug 19. PubMed PMID: 25201056.
3: Sundar S, Sinha PK, Dixon SA, Buckley R, Miller AK, Mohamed K, Al-Banna M. Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India. Am J Trop Med Hyg. 2011 Jun;84(6):892-900. doi: 10.4269/ajtmh.2011.10-0409. PubMed PMID: 21633025; PubMed Central PMCID: PMC3110365.
4: Vercesi AE, Docampo R. Ca2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochem J. 1992 Jun 1;284 ( Pt 2):463-7. PubMed PMID: 1376113; PubMed Central PMCID: PMC1132661.
5: Petty BG, Black JR, Hendrix CW, Lewis LD, Basiakos Y, Feinberg J, Pattison DG, Hafner R. Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173. J Acquir Immune Defic Syndr. 1999 May 1;21(1):26-32. PubMed PMID: 10235511.
6: Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, Price RN. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J. 2017 Sep 11;16(1):361. doi: 10.1186/s12936-017-2017-3. Review. PubMed PMID: 28893237; PubMed Central PMCID: PMC5594530.
7: López-Martín C, Pérez-Victoria JM, Carvalho L, Castanys S, Gamarro F. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrob Agents Chemother. 2008 Nov;52(11):4030-6. doi: 10.1128/AAC.00964-08. Epub 2008 Sep 15. PubMed PMID: 18794384; PubMed Central PMCID: PMC2573096.
8: Taylor T, Hawkins DR, Morris GR, Chung H. Pharmacokinetics of the anti-leishmanian agent WR 6026 in dogs. Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:136-9. PubMed PMID: 1820868.
9: Nqoro X, Tobeka N, Aderibigbe BA. Quinoline-Based Hybrid Compounds with Antimalarial Activity. Molecules. 2017 Dec 19;22(12). pii: E2268. doi: 10.3390/molecules22122268. Review. PubMed PMID: 29257067; PubMed Central PMCID: PMC6149725.
10: Loiseau PM, Cojean S, Schrével J. Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite. 2011 May;18(2):115-9. Review. PubMed PMID: 21678786; PubMed Central PMCID: PMC3671420.
11: Pérez-Victoria JM, Bavchvarov BI, Torrecillas IR, Martínez-García M, López-Martín C, Campillo M, Castanys S, Gamarro F. Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania. Antimicrob Agents Chemother. 2011 Aug;55(8):3838-44. doi: 10.1128/AAC.00065-11. Epub 2011 Jun 6. PubMed PMID: 21646479; PubMed Central PMCID: PMC3147638.
12: Baird JK. Tafenoquine for travelers’ malaria: evidence, rationale and recommendations. J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay110. PubMed PMID: 30380095; PubMed Central PMCID: PMC6243017.
13: Coimbra ES, Libong D, Cojean S, Saint-Pierre-Chazalet M, Solgadi A, Le Moyec L, Duenas-Romero AM, Chaminade P, Loiseau PM. Mechanism of interaction of sitamaquine with Leishmania donovani. J Antimicrob Chemother. 2010 Dec;65(12):2548-55. doi: 10.1093/jac/dkq371. Epub 2010 Oct 18. PubMed PMID: 20956354.
14: Garnier T, Brown MB, Lawrence MJ, Croft SL. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. J Pharm Pharmacol. 2006 Aug;58(8):1043-54. PubMed PMID: 16872550.
15: Mesquita JT, Tempone AG, Reimão JQ. Combination therapy with nitazoxanide and amphotericin B, Glucantime®, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes. Acta Trop. 2014 Feb;130:112-6. doi: 10.1016/j.actatropica.2013.11.003. Epub 2013 Nov 13. PubMed PMID: 24239532.
16: Kulshrestha A, Singh R, Kumar D, Negi NS, Salotra P. Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine. Antimicrob Agents Chemother. 2011 Jun;55(6):2916-21. doi: 10.1128/AAC.00812-10. Epub 2011 Apr 4. PubMed PMID: 21464251; PubMed Central PMCID: PMC3101468.
17: Graves PM, Choi L, Gelband H, Garner P. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2018 Feb 2;2:CD008152. doi: 10.1002/14651858.CD008152.pub5. Review. PubMed PMID: 29393511; PubMed Central PMCID: PMC5815493.
18: Chu CS, White NJ. Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304. Epub 2016 Aug 31. Review. PubMed PMID: 27530139; PubMed Central PMCID: PMC5039400.
19: Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. Malar J. 2018 Mar 2;17(1):101. doi: 10.1186/s12936-018-2248-y. Review. PubMed PMID: 29499733; PubMed Central PMCID: PMC5833093.
20: Wasunna MK, Rashid JR, Mbui J, Kirigi G, Kinoti D, Lodenyo H, Felton JM, Sabin AJ, Albert MJ, Horton J. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg. 2005 Nov;73(5):871-6. Erratum in: Am J Trop Med Hyg. 2006 Jan;74(1):185. Albert, M John [added]. PubMed PMID: 16282296.